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Abstract Protein kinase Cζ (ΡΚ€ζ) , a member of the atypical 
PKC subgroup, is insensitive to Ca2 + , diacylglycerol, and 
phorbol esters, but is activated by phospholipids such as 
phosphatidylinositol-3,4,5-triphosphate, a product of phosphati-
dylinositol 3-kinase (PI3-kinase). Here we show that ΡΚΟζ 
translocates from the cytosol to the 1 0 0 0 x # pellet (nuclear-
myofibrillar) fraction during ischemia for 40 min in Langendorff-
perfused rat hearts. In addition, immunohistochemical observa-
tion shows that ischemia induces the translocation of ΡΚΟζ to 
the nucleus. The nuclear translocation during ischemia is 
inhibited in a dose-dependent manner by wortmannin ( 1 0 - 9 -
10 7 M), an inhibitor of PI3-kinase. 
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1. Introduction 
The protein kinase C (PKC) family consists of 12 P K C 
isoforms classified into three subgroups [1,2]. Conventional 
PKCs (cPKCs) (α, βΐ, βΙΙ, and γ) are activated by both 
C a 2 + and diacylglycerol (DG) or phorbol esters; novel 
PKCs (nPKCs) (δ, ε, η , Θ, and μ) are activated by phospha-
tidylserine (PS) and D G but lack the domain that confers 
Ca 2 + sensitivity; atypical PKCs (aPKCs) (ζ and ι/λ) are un-
affected by C a 2 + , D G , or phorbol ester but activated by phos-
pholipids such as PS or phosphatidylinositol-3,4,5-triphos-
phate (PIP3) [2-7]. PIP3 is formed from phosphat-
idylinositol-4,5-bisphosphate (PIP2) by phosphatidyhnositol 
3-kinase (PI3-kinase) in response to insulin, platelet derived 
growth factor, or other agonists [8,9]. Recently, Akimoto 
et al. have shown that PKCi /λ is activated through PI3-kinase 
[10]. However, it is still unclear whether PIP3 participates in 
the activation of Ρ Κ ΰ ζ isoform in vivo. 
In the heart, P K C regulates the stretch of contraction [11], 
gene expression [12,13], and ion channel function [14]. Ac-
cordingly, potential P K C substrates exist in various subcellu-
lar compar tments : myofibrils (troponin and myosin light 
chain) [15,16] and membranes (Ca 2 + channels and phospho-
lamban) [17,18]. P K C also seems to play an important role in 
ischemic heart. It has been reported that ischemia-reperfusion 
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injures the myocardium by Ca 2 + influx through a N a + / H + -
exchanger whose activity appears to be regulated by P K C [19-
21]. Fur thermore, cycles of brief ischemia and reperfusion 
(designated preconditioning) protect the myocardium against 
infarction caused by subsequent sustained ischemia. The pre-
conditioning effect is suppressed by selective P K C inhibitors 
[22]. Although P K C isoforms are known to be differentially 
expressed in various cells and regulated by distinct activators 
[23,24], the role of P K C isoforms in ischemic heart has been 
poorly elucidated. We have recently shown that PKCct, δ, and 
ε isoforms translocate during ischemia, and suggested that the 
Ca 2 + -dependent protease calpain was involved in the activa-
tion [25]. However, the activation of Ρ Κ ϋ ζ and its activator(s) 
during ischemia is unknown at present al though Ρ Κ ϋ ζ has 
been shown to be involved in signal transduction in various 
cell types [26,27]. 
In this study, we show that P K C ζ in the cytosol translo-
cated to the nucleus during ischemia and that the nuclear 
translocation was inhibited by wortmannin, an inhibitor of 
PI3-kinase. 
2. Materials and methods 
2.1. Materials 
Anti-PKCoc antibody and ΆχΑί-ΡΥΧΧ, antibody (CV) against amino 
acids 394-590 of human PKCζ were bought from Transduction Lab-
oratories Inc. (Kentucky, CA, USA), anti-PKCßl and ß2 antibody, 
anti-PKC8 antibody, anti-PKCe antibody, and anti-PKCζ antibody 
(V) against amino acids 577-592 of rat ΡΚϋζ from Life Technologies 
Inc. (Gaithersburg, MD). Anti-histone HI antibody was from Leinco 
Technologies Inc. and anti-MEK-1 antibody was from Update Bio-
technology Inc. The enhanced chemiluminescence (ECL) reaction kit 
assay, anti-mouse and anti-rabbit immunoglobulin G antibodies 
coupled to horseradish peroxidase, and protein A-Sepharose were 
brought from Amersham Co.; the Vecstain ABC kit was from Vector 
Laboratories (Burlingame, CA); the biotin blocking system was from 
Dako Co. (Carpenteria, CA). All other reagents were commercially 
available. 
2.2. Perfusion protocol 
Male Wistar rats weighing about 200 g were anesthetized with 
sodium pentobarbital. The aortas were cannulated and attached to 
a Langendorff apparatus. The hearts were perfused as previously re-
ported [28], and then were subjected to global ischemia for 10-40 min 
at 37°C. The hearts were quickly frozen in liquid nitrogen and stored 
at —70°C for later biochemical analyses. 
2.3. Subcellular fractionation 
Subcellular fractionation was performed at 4°C essentially as pre-
viously described [21,29]. The frozen hearts were minced and homog-
enized in 2 volumes of STE buffer (0.32 M sucrose, 10 mM Tris-HCl, 
pH 7.4, 1 mM EGTA, 2 mM EDTA, 5 mM NaN3, 10 mM ß-mer-
captoethanol, 20 μΜ leupeptin, 0.15 μΜ pepstatin A, 0.2 mM PMSF, 
50 mM NaF, and 1 mM orthovanadate and 0.4 nM microcystin as 
protein phosphatase inhibitor) with a Polytron homogenizer, mixed 
with 2 volumes of STE buffer, and centrifuged at 1000Xg for 10 min 
to obtain pellet (PI: nuclear-myofibrillar) and supernatant fractions. 
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The supernatants were further centrifuged at lOOOOOXg for 60 min to 
obtain supernatant (S: cytosolic) and pellet (P2: membrane) fractions. 
The PI and the P2 fractions were suspended in the STE buffer. 
2.4. Electrophoresis and immunoblotting 
The samples and prestained molecular mass standard (Bio-Rad) 
were electrophoresed in 7.5% polyacrylamide gels in the presence of 
SDS, and transferred to nitrocellulose membrane (0.45 μηι). The blots 
were blocked with 5% nonfat dry milk in Tris-buffered saline contain-
ing 0.02% Tween-20, and incubated with one of the antibodies diluted 
in 1% BSA in the same buffer. After washing the blots, the antigens 
were visualized with the ECL reaction kit. 
2.5. Immunohistochemistry 
Rat hearts were immersed in OCT compound (Miles) and rapidly 
frozen in liquid nitrogen. After sectioning at 6 μΜ, the specimens 
were fixed on glasses with PLP solution (0.02 M NaIO4/0.075 M 
phosphate buffer/2% paraformaldehyde) for 10 min at 4°C and then 
incubated with 0.3% H2O2 in phosphate-buffered saline for 30 min to 
quench the endogenous peroxidase activity. The specimens were 
blocked with 1.5% normal serum in PBS, then incubated with anti-
PKCC antibody (V), anti-MEK-1 antibody, or anti-histone HI anti-
body in 1% BSA in PBS for 1 h and immunostained with the avidin-
biotin peroxidase complex method using a Vectastatin kit. The per-
oxidase label was visualized by exposing the sections to diaminoben-
zidine. 
3. Results and discussion 
3.1. Identification and translocation of PKCL, in ischemic heart 
It has been reported that the mRNA for ΡΚΟζ is expressed 
in the cardiomyocytes of neonatal and adult rats [30], but the 
Fig. 1. Subcellular localization of PKCC in the ischemic heart. The subcellular fractions were prepared from hearts rendered ischemic for 0^10 
min, and subjected to immunoblotting with anti-PKCC antibody. A: A representative immunoblot without anti-PKCC antibody (V) against 
amino acids amino acids 577-592 of rat PKCC (lane a), with anti-PKCC antibody (V) (lane b), and with anti-PKCC antibody (V) and the im-
munizing peptide (lane c). B-E: Representative immunoblots with anti-PKCC antibody (C) (B), anti-PKCC antibody (CV) against amino acids 
394-590 of human PKCC (Q> anti-histone HI antibody (D), and anti-MEK-1 antibody (E). These figures show representative immunoblots 
from three independent experiments. F: Amounts of PKCC (°/°: t n e s u m of PI, P2, and S fractions of control heart, n = 3) densitometrically de-
termined from the immunoblots using anti-PKCC antibody (CV) ( T < 0 . 0 5 vs. control, meantS.E. , PI : nucleus-myofibril (o), P2: membrane 
( · ) , S: cytosol ( Δ ) ) . 
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Fig. 2. Immunohistochemical localization of ΡΚΟζ. Hearts were 
subjected to ischemia for 0 min (A, C, and D) or 40 min (B), and 
then cryosectioned, fixed with PLP solution (0.02 M NaIO4/0.075 M 
phosphate buffer/2% paraformaldehyde), and stained with anti-
ΡΚΟζ antibody (A and B), anti-MEK-1 antibody (C), and anti-his-
tone antibody (D) as described in Section 2. The figures show repre-
sentative stainings from three independent experiments (magnifica-
tion before reduction to column width: X800). 
protein is hardly detectable in the adult cardiomyocytes [23]. 
As shown in Fig. 1A,B, an an t i -PK^ antibody (V) against 
amino acids 577-592 of rat ΡΚΟζ recognizes a protein with 
an approximate molecular mass of 75 kDa by immunoblot-
ting, a finding consistent with a previous report in bovine 
kidney [31]. The staining was prevented by preadsorption of 
the an t i -PK^ antibody (V) with immunizing peptide (Fig. 
1A). The 82 kDa band appears to cross-react with PKCa, 
as previously described [32], since the band corresponding to 
the molecular weight of PKCa is strongly present in the nu-
clear-myofibrillar fraction after PMA treatment (data not 
shown), and the epitope against an t i -PK^ antibody (V) has 
moderate homology (31%) in the carboxy-terminal region of 
PKCa. PKCßl and ß2, which have the same homology (31%) 
for the epitope, were not detectable in the rat heart by im-
munoblotting using anti-PKCßl and ß2 antibody (data not 
shown). To confirm the expression of PKCζ, we carried out 
immunoblotting using an anti-PKCζ antibody (CV) against 
amino acids 394-590 of human ΡΚϋζ, distinct from the epi-
tope against anti-PKCζ antibody (V). Fig. 1C shows that the 
immunoblot with the anti-PKCζ antibody (CV) was similar to 
that with the 3 η ΐ ί - Ρ ^ ζ antibody (V) (Fig. IB). These obser-
vations show that PKCζ is expressed in the heart of adult rats 
weighing up to 200 g. The density of visualized protein by 
ECL was proportional to the amount of the protein in each 
fraction up to 100 μg under the assay conditions (relative 
coefficient: > 0.990). Electron microscopic observation 
showed that the 1000Xg pellet (PI: nuclear-myofibrillar frac-
tion) contained the nuclei and myofibrils, and that the 
lOOOOOXg pellet (P2: membrane fraction) included mem-
brane vesicles and mitochondria (data not shown). Histone 
HI, a nuclear protein, was mainly localized in the nuclear-
myofibrillar fraction (82.3 ± 3.1%, mean ± S.E., n = 8), and the 
recovery remained almost constant during ischemia (Fig. ID). 
MEK-1 used as a marker of cytosol protein was present in the 
cytosol fraction (S fraction), and could not be detected in the 
PI fraction and the P2 fraction (Fig. IE). In untreated hearts, 
PKCC predominates in the S fraction (60.2 ±4.9%, 
mean±S.E., w = 3); the PI fraction contains only 21.6 ±5.1% 
(« = 3, Fig. 1B,C,F). The amount of ΡΚϋζ in the PI fraction 
increased significantly after 40 min of ischemia, with a con-
comitant decrease in the amount of ΡΚϋζ in the S fraction. 
ΡΚϋζ in the membrane fraction (P2 fraction) remained at 
control levels during ischemia for 40 min. PKCζ in the P2 
fraction might not reflect cytosol contamination but may be 
associated with the membrane, since a cytosol protein, MEK-
1, could not be detected in the P2 fraction (Fig. IE) and 
ΡΚϋζ was released to the supernatant by Triton X-100 treat-
ment of P2 fraction (data not shown). The immunohistochem-
ical observation by anti-PKCζ antibody (CV) shows that 
PKCζ is localized in the cytosol and nucleus, with the nuclear 
staining enhanced after 40 min of ischemia (Fig. 2A,B), con-
sistent with those by ΡΚϋζ (V). The staining was similar to 
that by anti-histone HI antibody (Fig. 2D). The staining of 
ΡΚϋζ (V) was specifically blocked by preincubation with the 
immunizing peptide, and by only secondary antibody (data 
not shown). These results were similar to those in three in-
dependent experiments. The findings show that PKCζ trans-
locates from the cytosol to the nucleus in ischemic heart. Since 
the translocation of PKC is a well-established parameter for 
its activation, the findings also suggest that ΡΚϋζ might be 
activated by activator(s) generated during ischemia. 
3.2. Nuclear translocation of PKCi, during ischemia is blocked 
by a PI3-kinase inhibitor, wortmannin 
It was recently reported that PIP3, a PI3-kinase product, 
activates PKCζ in vitro [33]. A fungal metabolite, wortman-
nin, inhibits PI3-kinase and contributes to determining the 
Fig. 3. Effect of PI-3 kinase inhibitor on ΡΚΟζ translocation during 
ischemia. The PI fractions were prepared from hearts subjected to 
ischemia for 40 min in the presence in = 3) of wortmannin at the in-
dicated concentration, and subjected to immunoblotting using anti-
ΡΚΟζ antibody. The amounts of ΡΚΟζ were determined from the 
immunoblots by densitometric analysis (mean±S.E.). (*P<0.05 vs. 
control; P<0.05 vs. ischemia 40 min, mean±S.E.). 
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Fig. 4. Effect of PI-3 kinase inhibitor on the translocation of PKC isoforms during ischemia. The PI fractions were prepared from hearts sub-
jected to ischemia for 40 min in the presence (n = 2) or absence (w = 2) of wortmannin (100 nM), and subjected to immunoblottmg with anti-
PKCot (A), δ (B), ε (C), and ζ (D) antibodies. The amounts of PKC isoforms were determined from the immunoblots by densitometric analysis 
(mean ± S.E.). 
precise role of PI3-kinase in whole cells (e.g. 0^ ~ generation 
and glucose transport) [34]. We found that wortmannin inhib-
its the nuclear translocation of ΡΚϋζ during ischemia in a 
dose-dependent manner (1(Γ9-1(Γ7 Μ) (Fig. 3). The finding 
suggests that ΤΚΟζ may be activated by a PI3-kinase product, 
PIP3, during ischemia. PS also stimulates ΡΚϋζ several-fold 
in vitro, but it is unlikely that PS activates ΡΚΧ3ζ in vivo since 
phosphatidylethanolamine, which is present in excess of PS in 
the membrane, is known to block the stimulation of ΡΚΟζ by 
PS at an equal molecular ratio in vitro [33]. 
3.3. Effect of wortmannin on the translocation of PKC isoforms 
during ischemia 
PIP3 activates not only ΡΚΟζ but also PKC5 and PKCe in 
vitro, whereas the activity of PKCa is unaffected [35]. There-
fore, we examined the effect of wortmannin on the transloca-
tion of PKCa, δ, and ε isoforms after 40 min of ischemia (Fig. 
4). Ischemia induces the redistribution of PKCa and PKCe 
from the S fraction to the PI fraction. Wortmannin (100 nM) 
partially inhibits the translocation of PKCe, but actually en-
hances the translocation of PKCa. This observation can be 
explained as follows: since wortmannin blocks the metabolism 
of PIP2 to PIP3 by PI3-kinase during ischemia, the accumu-
lated PIP2 may be rapidly converted to DG, a potent activa-
tor of PKCa, by catalysis of phospholipase C. Recently, 
Cross et al. have reported that wortmannin inhibited phos-
pholipase A2 activity in vivo but not in vitro [36]. It is also 
possible that wortmannin may inhibit the release of arachi-
donic acid, another activator of Ρ ^ ζ during ischemia [31]. To 
further clarify the involvement of PIP3 in the Ρ ^ ζ activation, 
it might be necessary to determine the PIP3 level in vivo. 
3.4. Physiological implications 
In cardiomyocytes that have lost mitogenic activity, mito-
genic stimuli such as growth factors and mechanical stretch 
are known to lead to hypertrophy [37,38]. The Ρ ^ ζ isoform 
has recently been shown to be critical for mitogenic signal 
transduction [39]. Therefore, Ρ ^ ζ activation during ischemia 
may be involved in the hypertrophy that is often seen in 
patients with ischemic heart disease [40]. On the other hand, 
tumor necrosis factor activates sphingomyelinase, generating 
ceramide [41]. Ceramide induces apoptosis and DNA frag-
mentation [42], and activates PKCC in vitro [26]. Moreover, 
PKCC is involved in the nuclear transport of nuclear tran-
scription factor KB, which is activated by the sphingomyeli-
nase pathway [27]. Since ischemia-reperfusion has been shown 
to induce apoptotic cell death [43], ΡΚΰζ might be involved in 
the signaling pathway of apoptosis in the ischemic heart. Re-
cently, we also reported that PKCa, δ, and e isoforms differ-
entially localized during ischemia in the heart [25]. It will be of 
interest to clarify the biological role of PKC isoforms during 
ischemia. 
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